Question 1

What are the potential benefits and risks of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer clinical trial (NCT05106296). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to other options available for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer clinical trial (NCT05106296). Contact the study team or your healthcare provider for specific answers.

Question 3

What kind of monitoring will be involved during the treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer clinical trial (NCT05106296). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for visits, and how long will the treatment last?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer clinical trial (NCT05106296). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any specific side effects I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer clinical trial (NCT05106296). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I experience side effects or if my condition worsens during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer clinical trial (NCT05106296). Contact the study team or your healthcare provider for specific answers.

What this study is about